PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION
暂无分享，去创建一个
M. Sadelain | A. Younes | R. Furman | B. Sénéchal | M. Palomba | C. Moskowitz | B. Santomasso | I. Rivière | J. Pineda | Y. Bernal | M. Hall | C. Diamonte | E. Halton | E. Mead | X. Wang | R. Brentjens | C. Batlevi | N. Lund | J. Park | J. Yang | P. Kane